Scholarlink

Background <p>Around 40% of patients diagnosed with Primary Biliary Cholangitis (PBC) experience a suboptimal biochemical response to ursodeoxycholic acid (UDCA).</p> Aims <p>We aimed to compare fibrates and obeticholic acid (OCA) as add-on second-line therapy and evaluate whether these drugs hold superiority over each other<b>.</b></p> Methods <p>We systematically searched Embase, MEDLINE, and Cochrane CENTRAL for studies comparing fibrates and OCA published by May 6, 2024. A pooled analysis was conducted to evaluate changes in liver biochemistry and response rates based on validated criteria. Data were expressed as mean difference (MD) for continuous outcomes and as Odds Ratio (OR) when binary.</p> Results <p>We included 883 patients from 4 studies, 468 (53.0%) under UDCA + OCA. Follow-up time ranged from 6 to 12 months. Patients treated with fibrates have similar mean bilirubin post-intervention values (MD 0.11 × upper limit of normal [ULN]; 95% CI −&#xa0;0.26 to 0.49) compared to OCA. However, fibrates demonstrated superiority over OCA for percentual reduction in ALP compared to baseline (MD 20.13%; 95% CI 11.84–28.41), ALP post-intervention values (MD −&#xa0;0.59 xULN; 95% CI −&#xa0;1.02 to −&#xa0;0.15), and rate of ALP normalization (OR 32.34; 95% CI 14.54–71.92). Patients treated with fibrates also more frequently met Barcelona (OR 4.28; 95% CI 2.26–8.11), POISE (OR 5.48; 95% CI 2.70–11.13), and Paris II (OR 5.88; 95% CI 3.96–8.74) response criteria.</p> Conclusion <p>In patients with PBC and an incomplete response to UDCA, fibrates seem to be associated with greater ALP reduction and achievement of response criteria compared to OCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Obeticholic Acid vs Fibrates as Second-Line Therapy for Primary Biliary Cholangitis: Systematic Review and Meta-Analysis

  • 期刊论文

  • 发表日期：

    2025年4月19日

查看全文
  • Eliabe S. Abreu,
  • Pedro Henrique Reginato,
  • Jorge Ferreira Jasmineiro Pitanga,
  • Pedro Neves Borges,
  • Pierre-Antoine Soret,
  • Christophe Corpechot,
  • Guilherme Grossi Lopes Cançado

摘要

Background

Around 40% of patients diagnosed with Primary Biliary Cholangitis (PBC) experience a suboptimal biochemical response to ursodeoxycholic acid (UDCA).

Aims

We aimed to compare fibrates and obeticholic acid (OCA) as add-on second-line therapy and evaluate whether these drugs hold superiority over each other.

Methods

We systematically searched Embase, MEDLINE, and Cochrane CENTRAL for studies comparing fibrates and OCA published by May 6, 2024. A pooled analysis was conducted to evaluate changes in liver biochemistry and response rates based on validated criteria. Data were expressed as mean difference (MD) for continuous outcomes and as Odds Ratio (OR) when binary.

Results

We included 883 patients from 4 studies, 468 (53.0%) under UDCA + OCA. Follow-up time ranged from 6 to 12 months. Patients treated with fibrates have similar mean bilirubin post-intervention values (MD 0.11 × upper limit of normal [ULN]; 95% CI − 0.26 to 0.49) compared to OCA. However, fibrates demonstrated superiority over OCA for percentual reduction in ALP compared to baseline (MD 20.13%; 95% CI 11.84–28.41), ALP post-intervention values (MD − 0.59 xULN; 95% CI − 1.02 to − 0.15), and rate of ALP normalization (OR 32.34; 95% CI 14.54–71.92). Patients treated with fibrates also more frequently met Barcelona (OR 4.28; 95% CI 2.26–8.11), POISE (OR 5.48; 95% CI 2.70–11.13), and Paris II (OR 5.88; 95% CI 3.96–8.74) response criteria.

Conclusion

In patients with PBC and an incomplete response to UDCA, fibrates seem to be associated with greater ALP reduction and achievement of response criteria compared to OCA.